Heterobifunctional E-selectin Galectin-3 Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current modulators for E-selectin and galectin-3, such as PSGL-1 protein, fucoidan, and glycyrrhizin, are unsuitable for drug development due to insufficient activity, toxicity, lack of specificity, poor ADME characteristics, and availability issues, necessitating the development of effective inhibitors for these proteins to treat inflammatory diseases and cancers.
Innovation Solution
Development of heterobifunctional compounds that inhibit both E-selectin and galectin-3 by linking an E-selectin inhibitor with a galectin-3 inhibitor, providing a pharmaceutical composition for administering these compounds to treat and prevent diseases associated with excessive cell adhesion and inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current modulators (PSGL-1 protein, fucoidan, glycyrrhizin) are used to inhibit E-selectin and galectin-3, then some inhibitory activity is achieved, but they suffer from insufficient activity, toxicity, lack of specificity, poor ADME characteristics, and availability issues
Solution Approach 1:
The patent combines two separate inhibitor molecules into a single heterobifunctional compound that can simultaneously target both E-selectin and galectin-3. This merging approach allows the compound to achieve reliable inhibitory activity against multiple targets while maintaining favorable pharmacological properties, avoiding the toxicity and insufficient activity problems of individual modulators.
Solution Approach 2:
The invention creates a composite molecular structure consisting of two distinct inhibitor moieties linked together. This composite design integrates the functional advantages of both inhibitor components, producing a molecule with enhanced and balanced activity profile that overcomes the limitations of single-modulator approaches.
2Reliability
If current modulators are used, then some inhibitory effect is achieved, but they exhibit lack of specificity and poor ADME characteristics
Solution Approach 1:
By merging two specific inhibitor components into one heterobifunctional molecule, the compound achieves dual specificity for E-selectin and galectin-3. This approach ensures that the inhibitor selectively targets the intended proteins without affecting other biological systems, resolving the specificity problem while maintaining reliable inhibitory activity.
3Reliability
If current modulators are used, then some activity is achieved, but they have poor ADME characteristics and availability issues
Solution Approach 1:
The patent optimizes the physicochemical parameters of the inhibitor molecules by carefully selecting the linker properties and adjusting the molecular weight, lipophilicity, and structural characteristics of the heterobifunctional compound. These parameter changes improve ADME characteristics while preserving the essential inhibitory activity, making the compound suitable for drug development.
Data Source
AI summary
Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin, galectin-3, or E-selectin and galectin-3 to ligands are disclosed. For example, heterobifunctional inhibitors of E-selectin and galectin-3 are described and pharmaceutical compositions comprising at least one such agent is described.